Erytech reports additional Phase IIb data for eryaspase in pancreatic cancer

In September, Erytech Pharma S.A. (Euronext:ERYP) reported additional data from a Phase IIb trial to treat progressive metastatic pancreatic cancer showing that second-line treatment with eryaspase (Graspa, ERY-ASP, ERY001) plus standard of care (SOC) gemcitabine or FOLFOX chemotherapy met the secondary endpoints of improving median progression-free survival (PFS) (8.6 vs. 7 weeks, HR=0.59, 95% CI: 0.4, 0.89, p=0.011) and overall survival (OS) (26.1 vs. 19 weeks, HR=0.6, 95% CI: 0.4, 0.88, p=0.009) in the entire 141-patient population vs. SOC alone. On secondary endpoints in the entire patient population, eryaspase plus SOC led to an objective response rate (ORR) and disease control rate (DCR) of 11.6% and 47.4%, respectively, vs. 6.5% and 23.9% for SOC alone. Data were presented at the European Society for Medical Oncology meeting in Madrid.

Erytech previously reported that eryaspase plus SOC met the co-primary endpoints of improving PFS (8.6 vs. 7.6 weeks, HR=0.72, 95% CI: 0.44, 1.17, p=0.184) and OS (27 vs. 21.7 weeks, HR=0.65, 95% CI: 0.4, 1.05, p=0.077) in patients with zero or low levels of asparagine synthetase (ASNS) (n=98) vs. SOC alone. The pre-specified threshold for meeting the endpoints was an HR of <0.85, irrespective of statistical significance. In patients with zero or low levels of ASNS, eryaspase plus SOC led to an ORR and DCR of 13.6% and 45.5%, respectively, vs. 9.4% and 31.3% for SOC alone (see BioCentury, March 30)...